Zuckerberg San Francisco General Hospital
Zuckerberg San Francisco General Hospital
San Francisco, California, United States42 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-09 | NCT06806033 | |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma | Recruiting | Phase 3 | 2026-10-09 | NCT06058377 | |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Blood-Borne Infections, Digestive System Diseases, Digestive System Neoplasms, Genital Diseases, HIV infectious disease, Infections, Neoplasms by Site, RNA Virus Infections, Urogenital Diseases, anal margin squamous cell carcinoma, anal squamous cell carcinoma, anus disorder, anus neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, immune system disorder, inborn error of immunity, infectious disease, intestinal disorder, lentivirus infection, neoplasm, rectal disorder, rectal neoplasm, sexually transmitted disease, squamous cell carcinoma of rectum, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Active, not recruiting | Phase 2 | 2026-10-05 | NCT04929028 | |
| Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, immune system disorder, neoplasm | Recruiting | Not stated | 2026-10-05 | NCT04242095 | |
| Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy | invasive breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04379570 | |
| Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03793179 | |
| Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, anal margin squamous cell carcinoma, anus basaloid carcinoma, anus disorder, anus neoplasm, cloacogenic carcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03233711 | |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | breast adenocarcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00433511 | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00310180 | |
| CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy | invasive breast carcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT04266249 | |
| Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer | Breast Screening | Active, not recruiting | Phase 3 | 2026-09-04 | NCT03233191 | |
| The Heart Health After Cardiac Treatment Study | Cardiac Rehabilitation | Active, not recruiting | Not applicable | 2026-09-02 | NCT07158515 | |
| Implementation Strategies for Self-Measured Blood Pressure Monitoring in Racially and Ethnically Diverse Populations | Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Aspiration, cardiovascular disorder, hypertensive disorder, respiratory system disorder, vascular disorder | Enrolling by invitation | Not applicable | 2026-08-21 | NCT06871462 | |
| Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER) | COVID-19, Chronic Disease, Coronaviridae Infections, Disease Attributes, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, RNA Virus Infections, long COVID-19, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Not stated | 2026-08-18 | NCT07770022 | |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma | Recruiting | Phase 3 | 2026-08-05 | NCT05812807 | |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, carcinosarcoma, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, mixed neoplasm, neoplasm, sarcoma, uterine disorder | Active, not recruiting | Phase 3 | 2026-07-31 | NCT03914612 | |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Anorexia, Hemic and Lymphatic Diseases, Neoplasms by Site, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-07-30 | NCT04939090 | |
| PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Status Epilepticus, cardiac arrest, cardiovascular disorder, heart disorder, nervous system disorder, visual epilepsy | Recruiting | Phase 2 | 2026-07-29 | NCT06401707 | |
| buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest | Anoxia-Ischemia, Cerebral, Anoxic-Ischemic Encephalopathy, Hypoxia, Hypoxia, Brain, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Respiratory, Status Epilepticus, brain disorder, brain hypoxia - ischemia, brain ischemia, cardiac arrest, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, nervous system disorder, vascular disorder, visual epilepsy | Recruiting | Phase 2 | 2026-07-29 | NCT05851391 | |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-07-23 | NCT03975647 | |
| Duraplasty for Acute Traumatic Spinal Cord Injury | central nervous system disorder, injury, nervous system disorder, nervous system injury, spinal cord disorder, spinal cord injury | Enrolling by invitation | Not applicable | 2026-07-21 | NCT07280351 | |
| Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures | Healthy | Recruiting | Not applicable | 2026-06-16 | NCT06030674 | |
| Melanin and Dermal Uptake of Thirdhand Cigarette Smoke | Healthy | Recruiting | Not applicable | 2026-06-16 | NCT06020248 | |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | HER2 positive breast carcinoma, invasive breast carcinoma, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-06-15 | NCT04457596 | |
| Safety of Transcutaneous Electrical Stimulation Potentiating Recovery in Acute Spinal Cord Injury Syndromes | Acute Spinal Cord Injury (SCI); Acute Spinal Cord Injury of Traumatic Origin (tSCI) | Recruiting | Not applicable | 2026-06-04 | NCT07090473 |